Know more

About cookies

What is a "cookie"?

A "cookie" is a piece of information, usually small and identified by a name, which may be sent to your browser by a website you are visiting. Your web browser will store it for a period of time, and send it back to the web server each time you log on again.

Different types of cookies are placed on the sites:

  • Cookies strictly necessary for the proper functioning of the site
  • Cookies deposited by third party sites to improve the interactivity of the site, to collect statistics

Learn more about cookies and how they work

The different types of cookies used on this site

Cookies strictly necessary for the site to function

These cookies allow the main services of the site to function optimally. You can technically block them using your browser settings but your experience on the site may be degraded.

Furthermore, you have the possibility of opposing the use of audience measurement tracers strictly necessary for the functioning and current administration of the website in the cookie management window accessible via the link located in the footer of the site.

Technical cookies

Name of the cookie


Shelf life

CAS and PHP session cookies

Login credentials, session security



Saving your cookie consent choices

12 months

Audience measurement cookies (AT Internet)

Name of the cookie


Shelf life


Trace the visitor's route in order to establish visit statistics.

13 months


Store the anonymous ID of the visitor who starts the first time he visits the site

13 months


Identify the numbers (unique identifiers of a site) seen by the visitor and store the visitor's identifiers.

13 months

About the AT Internet audience measurement tool :

AT Internet's audience measurement tool Analytics is deployed on this site in order to obtain information on visitors' navigation and to improve its use.

The French data protection authority (CNIL) has granted an exemption to AT Internet's Web Analytics cookie. This tool is thus exempt from the collection of the Internet user's consent with regard to the deposit of analytics cookies. However, you can refuse the deposit of these cookies via the cookie management panel.

Good to know:

  • The data collected are not cross-checked with other processing operations
  • The deposited cookie is only used to produce anonymous statistics
  • The cookie does not allow the user's navigation on other sites to be tracked.

Third party cookies to improve the interactivity of the site

This site relies on certain services provided by third parties which allow :

  • to offer interactive content;
  • improve usability and facilitate the sharing of content on social networks;
  • view videos and animated presentations directly on our website;
  • protect form entries from robots;
  • monitor the performance of the site.

These third parties will collect and use your browsing data for their own purposes.

How to accept or reject cookies

When you start browsing an eZpublish site, the appearance of the "cookies" banner allows you to accept or refuse all the cookies we use. This banner will be displayed as long as you have not made a choice, even if you are browsing on another page of the site.

You can change your choices at any time by clicking on the "Cookie Management" link.

You can manage these cookies in your browser. Here are the procedures to follow: Firefox; Chrome; Explorer; Safari; Opera

For more information about the cookies we use, you can contact INRAE's Data Protection Officer by email at or by post at :


24, chemin de Borde Rouge -Auzeville - CS52627 31326 Castanet Tolosan cedex - France

Last update: May 2021

Menu Logo Principal Oniris

Home page

Epidemiological modelling and its use to manage COVID-19

Insights into mechanistic models, by the DYNAMO team

Over the next few weeks, we will present some key elements of epidemiological modelling through short educational articles. These articles will help you to better understand and decipher the assumptions underlying the epidemiological models that are currently widely used, and how these assumptions can impact predictions regarding the spread of pathogens, particularly SARS-CoV-2. The objective is to discover the advantages and limitations of mechanistic modelling, an approach that is at the core of the DYNAMO team's work. The examples of models will be inspired by models used in crisis, but sometimes simplified to make them accessible.

#5 – Why represent the heterogeneity of infected individuals in the model? (1/2)

We have seen that it is often difficult to determine the values of model parameters. However, many of the models mobilized during the COVID19 crisis (as well as for other epidemiological systems) rather finely represent the heterogeneity of infected individuals, thus increasing the complexity of the model.

Let us take the following example: instead of the two states A and I considered in the previous articles (article #1), let's now add a latency phase E and an incubation phase E+Ip. Individuals E are infected, but are not yet excreting and have no symptoms. As for individuals Ip, they begin to excrete before any symptoms appear. We maintain the distinction between a- or pauci-symptomatic individuals (Ia) and symptomatic individuals (Is), the latter being the only ones at risk of dying from the infection.

Schéma de modélisation incluant une phase de latence

This epidemiological model considers 7 states: susceptible (S), latent infected non-shedders (E), incubating infected shedders (without symptoms, Ip), a- or pauci-symptomatic  infected shedders (Ia), symptomatic infected shedders (Is), cured (R), and dead (M). The strength of infection (λ) takes into account the different contributions of shedder individuals (Ip, Ia, Is) to new infections.

This model necessarily has more parameters (9 instead of 6 parameters previously) and more states (7 instead of 5). It is therefore more complicated (it is also said to be less parcimonious). Often, additional assumptions can reduce the complexity to make it more relevant to available knowledge. For example, it can be assumed that shedder individuals without symptoms (Ip and Ia) have the same excretion levels (thus βp = βa) in the absence of further information.

But why complicate the model? Two elements explain it from a methodological point of view:

  • The contribution of infected individuals to new cases may differ according to the stage of infection, which is difficult to take into account without distinguishing between these stages. For example, at the beginning of the infection (stage E), individuals are no longer susceptible (i.e. cannot become infected) but do not shed the pathogen yet (i.e. do not contribute to new cases), which will lead to a delay in the onset of the epidemic.
  • Markov-type compartment models (without memory) assume an exponential distribution of durations in the compartments, which is not very realistic. (article #1). To remedy this rigorously, the underlying mathematical formalism (delay models) would have to be changed. An alternative to reduce the impact of this hypothesis is to consider several successive sub-states, since a sum of durations following exponential distributions converges quickly enough to a quasi-constant duration.

What is the impact of the change in model structure on predictions? 

Let us compare for example the model described in the figure above (black curve below), explicitly considering a latent phase without shedding (E) followed by a pre-symptomatic shedding phase (Ip), with a model integrating E and Ip in a single phase Ip2 which then represents the entire incubation period (red curve). Let's update the parameters relating to Ip2 so that the two models are comparable. The duration in Ip2 becomes: dp2 = dp1 + dE, with dp1 = 1/γp and dE = 1/ε. The transmission rate integrates that E individuals do not shed during dE: βp2 = (βp1dp1) / (dE + dp1).

Nombre de décès cumulés par jour en considérant (en noir) ou non (en rouge) une phase de latence

Prediction of models explicitly including the latency phase E (in black) or not (in red): the epidemic predicted by the red model starts faster than the one predicted by the black model, while the parameters are comparable.

We can clearly see the delaying effect of the latency phase on the epidemic dynamics. It is therefore essential to have as much precise biological knowledge as possible about the course of the infection in the host in order to know whether such a latency phase is relevant or not and how long it lasts.

Article #6 will continue this discussion, taking into account factors that increase the complexity of models in relation to their realism and their use in health management.